Article
Author: Li, Peng ; Zheng, Runhui ; Huang, Jiayu ; Chen, Ao ; Tan, Huo ; Luo, Xiaodan ; Chen, Sihui ; Qin, Le ; Qin, Dajiang ; Shi, Boyun ; Tang, Zhaoyang ; Ye, Ting ; Tang, Jianli ; Liu, Jianbo ; Zhao, Rong ; Weinkove, Robert ; Yuan, Danyun
This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.